---
title: "Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294814748.md"
description: "Beam Therapeutics reported Q2 2026 results with $0.5M revenue and a net loss of $(122.7) M, or $(1.18) diluted EPS. Revenue declined significantly from the prior year. Clinically, BEACON risto-cel dosing completed with promising data, targeting a BLA filing by year-end 2026. In vivo candidates are advancing, supported by a new cGMP facility and strategic collaborations providing non-dilutive funding."
datetime: "2026-08-04T11:21:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294814748.md)
  - [en](https://longbridge.com/en/news/294814748.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294814748.md)
generator: "portal-rs"
---

# Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary

Beam Therapeutics Inc. reported results for the second quarter of 2026 with revenue of $0.5M and a net loss attributable to Beam of $(122.7) M, producing a diluted loss per share of $(1.18) versus the year‑ago quarter.

**Financial Highlights**

-   Revenue: $0.5M for 2Q 2026, down from $8.5M in 2Q 2025 (‑$8.0M YoY).
-   Net income: Net loss attributable to Beam of $(122.7) M for 2Q 2026 versus net loss of $(102.1) M in 2Q 2025.
-   Diluted EPS: $(1.18) loss per share for 2Q 2026 versus $(1.00) loss per share in 2Q 2025.

**Business Highlights**

-   Clinical progress: BEACON risto‑cel Phase 1/2 completed dosing with durable high editing, hemoglobin F levels above 60% and reduced HbS; a BLA filing is targeted for year‑end 2026.
-   LNP program momentum: In vivo liver‑targeted candidates BEAM‑302, ‑304 and ‑301 are advancing, with BEAM‑302 moving into a pivotal expansion cohort.
-   Manufacturing and operations: A 100k sq ft cGMP facility is online to support both ex vivo and in vivo programs and potential commercial supply.
-   Collaborations and licensing: Strategic alliances with Pfizer, Lilly/Verve, Apellis/Biogen and Orbital/BMS continue to provide program support and non‑dilutive milestone revenue.
-   Funding and revenue mix: License and collaboration revenue growth was driven by a Lilly milestone; capital raises and an equity sales agreement support the company’s R&D runway.

Original SEC Filing: Beam Therapeutics Inc. \[ BEAM \] - 10-Q - Aug. 04, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BEAM.US](https://longbridge.com/en/quote/BEAM.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [VERV.US](https://longbridge.com/en/quote/VERV.US.md)
- [APLS.US](https://longbridge.com/en/quote/APLS.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results](https://longbridge.com/en/news/295256769.md)
- [Beam Therapeutics Q2 FY26 net loss widens to $122.7 million; revenue drops to $490,000](https://longbridge.com/en/news/294811887.md)
- [Beam Communications Declares Dividend for FY2026 Shareholders](https://longbridge.com/en/news/296546543.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**